Monthly Healthcare Review
October 2017
Company NameLast Financing
DateHQ Location Description
Last
Financing
Size
(Millions)
Lead Manager
InflaRx (IFRX) 13-Oct-17 Jena, Germany
Developer of therapeutics in the field of acute and chronic inflammation designed to
prevent organ dysfunction or limit progression into organ failure. 100.01
J.P Morgan, Leerink
Partners, BMO
Capital Markets
OptiNose (OPTN) 13-Oct-17 Yardley, PA
Developer of exhalation delivery systems capable of high and deep intranasal deposition of
medication. 120.00
BMO Capital
Market, Jefferies,
Piper Jaffray & Co.,
RBC Capital
Markets
The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.
IPOs
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 1
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
KSQ Therapeutics 2-Oct-17 Cambridge, MA Early Stage VC
Developer of an industrialized functional genomics engine that utilizes a
suite of proprietary CRISPR/Cas9 tools to identify novel pathways and
targets involved in oncology and immuno-oncology. 76.00
Flagship Pioneering,
Polaris Partners,
ARCH Venture
Partners, Alexandria
Equities
Locus Biosciences 2-Oct-17
Research Triangle
Park, NC Early Stage VC
Developer of sequence-specific precision antimicrobials for human
infectious diseases. 7.00
Tencent, North
Carolina Biotech
Center, Undisclosed
Investors
Peptide Logic 2-Oct-17 San Diego, CA
Accelerator/
Incubator
Owner and operator of a biopharmaceutical company that combines the
advantages of synthetic peptides and recombinant antibodies to create
innovative semi-synthetic biologics for the treatment of chronic pain. Undisclosed JLABS
Recombinetics 2-Oct-17 Saint Paul, MN Angel
Developer of gene editing technologies designed to manipulate
deoxyribonucleic acid samples to add and activate genes to solve problems
in biomedical research, livestock productivity, and animal-derived
biomaterials for use in medical applications. 0.08
Undisclosed
Investors
Cullinan Oncology 3-Oct-17 Boston, MA Early Stage VC
Developer of externally sourced cancer therapeutics intended to end a
drug program quickly if the early research suggests it won't work. 150.00
MPM Capital, F2
Ventures,
Undisclosed
Investors
Dominion Aesthetic
Technologies 3-Oct-17 San Antonio, TX Angel
Supplier of aesthetic medical devices designed to improve a patient's
interface and mobility. 1.60
Florida Institute for
the
Commercialization
of Public Research,
Undisclosed
Investors
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 2
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Harbor MedTech 3-Oct-17 Irvine, CA Early Stage VC
Operator of a medicine company that provides wound healing and tissue
regeneration products. 5.37
Arsenal Capital
Management,
Undisclosed
Investors
InfiCure Bio 3-Oct-17 Umeå, Sweden
PE Growth/
Expansion
Developer of a pre-clinical mouse model that evaluates the effects of anti-
fibrotic drugs. Undisclosed
Partnerinvest Norr,
Northen Light
Capital, Vinnova
Invenra 3-Oct-17 Madison, WI Later Stage VC
Developer of a platform to screen peptides and proteins to discover and
develop new biologic drugs in areas like cancer, Alzheimer's disease, and
diabetes. 2.93
Undisclosed
Investors
Recursion
Pharmaceuticals 3-Oct-17 Salt Lake City, UT Early Stage VC
Provider of a drug discovery platform that uses biological tools to build
cellular disease models, enabling biologists to query and understand the
results of phenotypic screens, drug screens, and target discovery screens
with immediate access to raw images and underlying data. 60.00
Data Collective, Lux
Capital, Obvious
Ventures,
Advantage Capital,
Felicis, Epic, AME
Cloud Ventures,
Mubadala, Menlo
Ventures, Charles
River Ventures, Two
Sigma, Undisclosed
Investors
Thc Biomed
International 3-Oct-17 Kelowna, Canada PIPE
Producer of medical marijuana and provider of scientific research and
services related to the medical cannabis industry. 0.65 Alumina Partners
Imagin Medical (IME) 4-Oct-17 Vancouver, Canada PIPE
Developer of a technology intended for the early detection of cancer
through the use of endoscopes. 0.73
Undisclosed
Investors
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 3
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Immatics 4-Oct-17 Tübingen, Germany Later Stage VC
Developer of immunotherapies designed to use the body's own immune
system to fight cancer. 58.00
Amgen, Wellington
Partners, dievini
Hopp BioTech, AT
Impf, Undisclosed
Investors
Koutif Therapeutics 4-Oct-17 Cleveland, OH Angel
Operator of a drug discovery company intended to fight inflammatory
diseases. 0.60
Undisclosed
Investors
OMEICOS
Therapeutics 4-Oct-17 Berlin, Germany Early Stage VC
Developer of a first-in-class small molecule therapy designed for the
treatment and prevention of atrial fibrillation. Undisclosed
Remiges Ventures,
Vesalius Biocapital
Partners and SMS
Group; SICAR,
High-Tech
Gründerfonds, KfW
Bankengruppe, IBB
Beteiligungsgesellsch
aft, The Falck
Revocable Trust,
Ascenion,
Undisclosed
Investors
Palleon Pharmaceuticals 4-Oct-17 Waltham, MA Early Stage VC
Developer of a biotechnology platform designed to offer a wider range of
rational combination therapies to treat cancer and tackle resistance to first-
generation immuno-oncology agents. 47.60
SR One, Pfizer,
Vertex Ventures
HC, Takeda
Ventures, AbbVie
Ventures
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 4
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
3T Biosciences 5-Oct-17 Palo Alto, CA Seed Round
Provider of medical research and development facilities that incorporate
synthetic biology and machine learning to discover novel targets in order to
cure cancer and other T-cell mediated diseases. 12.00
Thiel CapitaL, Asset
Management
Ventures, Sean
Parker, Undisclosed
Investors
Harmony Biosciences 5-Oct-17
Plymouth Meeting,
PA Early Stage VC
Developer of biopharmaceuticals designed to identify, develop, and
commercialize novel treatment options for patients with rare central
nervous system disorders. 270.00
Valor Equity
Partners, Fidelity
Management &
Research, HBM
Healthcare
Investments, Vivo
Capital, venBio,
Novo, Nan Fung
Capital, Paragon
Biosciences,
California Institute
for Quantitative
Biosciences
SCA Pharmaceuticals 5-Oct-17 Little Rock, AR
PE Growth/
Expansion
Developer of unit dosed oral syringes, drug shortage medications, and
compounded pharmaceutical products for hospitals, pharmacies, and
ambulatory surgery centers. Undisclosed
Enhanced Equity
Funds
Calcivis 6-Oct-17
Edinburgh, United
Kingdom Later Stage VC
Developer of a dental imaging system designed to transform the
assessment and management of demineralization associated with dental
caries and erosion. 1.63
Archangels Informal
Investment, Scottish
Enterprise, Julz,
Undisclosed
Investors
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 5
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
PanOptica 6-Oct-17 Bernardsville, NJ Early Stage VC
Provider of therapies for debilitating vision loss, age-related muscular
degeneration, and diabetic retinopathy. 11.00
SV Life Sciences
Advisers, Third
Rock Ventures
Qidni Labs 6-Oct-17 Kitchener, Canada
Accelerator/
Incubator
Developer of renal replacement therapy devices for patients with end-stage
renal disease. 0.55 43North
Sequella 6-Oct-17 Rockville, MD Later Stage VC
Developer of antibiotics for the treatment of tuberculosis and gastritis
infections. 0.63
Undisclosed
Investors
Blaze Bioscience 9-Oct-17 Seattle, WA Later Stage VC
Developer of a cancer surgery technology providing real-time, high
resolution visualization of cancer cells for surgeons to achieve better
resection of tumors while simultaneously preserving healthy tissues. 16.11
Undisclosed
Investors
MT-Medikals 9-Oct-17 Moscow, Russia Early Stage VC
Operator of a biotechnology firm intended to provide treatment of
multidrug-resistant tuberculosis. 0.19
Primer Capital,
Undisclosed
Investors
Sygnature Discovery 9-Oct-17
Nottingham, United
Kingdom
PE Growth/
Expansion Provider of integrated drug discovery and research services. Undisclosed
Phoenix Equity
Partners
Theraworx 9-Oct-17 Asheville, NC Later Stage VC
Provider of specialty care packs for peri-care prior to foley catheter
insertion and on-going foley maintenance. 41.57
Asgard Partners,
Undisclosed
Investors
Azura Ophthalmics 10-Oct-17 Tel Aviv, Israel Early Stage VC
Developer of innovative therapies for the treatment of meibomian gland
dysfunction. 16.00
TPG Biotech,
Brandon Capital,
OrbiMed, Ganot
Capital
Crescita Therapeutics 10-Oct-17 Mississauga, Canada
Secondary
Transaction -
Private
Provider of a portfolio of non-prescription skincare products and
prescription drug products for the treatment and care of skin conditions
and diseases. Undisclosed Knight Therapeutics
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 6
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Engage Therapeutics 10-Oct-17 Summit, NJ Early Stage VC
Developer of a new drug-device combination therapy for people who
experience uncontrolled epileptic seizures. 23.60
TPG Biotech,
Adage Capital
Management,
Lifescivc, Lumira
Capital, Undisclosed
Investors
InjectSense 10-Oct-17 Emeryville, CA Angel
Developer of an injectable wireless pressure sensor designed to monitor
patient IOP profiles for glaucoma by focusing on minimally invasive
assistance to generate clinically actionable information for therapy
management and outcome. 9.84
Undisclosed
Investors
KalVista (KALV) 10-Oct-17
Porton Down,
United Kingdom PIPE
Developer of small-molecule pharmaceuticals designed for a variety of
hereditary diseases. 9.10 Merck & Co
Ribon Therapeutics 10-Oct-17 Lexington, MA Early Stage VC
Developer of novel therapeutics targeting monoADP-ribosylating PARPs
for cancer. 43.50
US Venture
Partners, Deerfield
Management, Osage
University Partners,
The Column Group,
Undisclosed
Investors
Wellesley
Pharmaceuticals 10-Oct-17 Newtown, PA Later Stage VC Developer of drugs for the treatment of nocturia. 3.78
Axella Bioventures,
Undisclosed
Investors
Asepticys 11-Oct-17 New Orleans, LA Early Stage VC
Developer of medical disinfection products that kill and deactivate
pathogenic organisms across all microbial kingdoms and are effective
across a broad spectrum of microbial pathogens. 2.65
Undisclosed
Investors
Biophytis (ALBPS) 11-Oct-17 Paris, France PIPE Developer of drugs for metabolic disorders and age-related diseases. 12.40
Undisclosed
Investors
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 7
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
GrowHealthy 12-Oct-17 Lake Wales, FL Corporate
Operator of a marijuana farm offering medical marijuana, clinics, and
pharmaceutical-grade medical marijuana cannabis-infused products. 6.00
iAnthus Capital
Management
Janpix 12-Oct-17
London, United
Kingdom Early Stage VC Devleoper of therapies to treat hematological tumors and glioblastomas. 17.70
Medicxi Ventures,
Undisclosed
Investors
LabGenius 12-Oct-17
London, United
Kingdom Angel
Provider of a closed-loop platform intended to develop a new generation
of biological products using artificial intelligence, automation, and synthetic
DNA. 2.77
Undisclosed
Investors
Realm Therapeutics
(RLM) 12-Oct-17 Malvern, PA PIPE
Develper of small molecule therapies for the treatment of inflammatory
diseases with potential applications in dermatology, ophthalmology, and
other diseases. 26.00
OrbiMed, BVF
Partners, RA Capital
Management,
Abingworth
BioEquities Master
Fund, Polar Capital
Techulon 12-Oct-17 Blacksburg, VA Angel
Operator of a biotechnology platform that facilitates delivery of nucleic
acids for a variety of therapeutic applications, enabling researchers to
develop a targeted approach to inhibit growth of common MDR bacteria
and new strains of bacteria. 0.20
Undisclosed
Investors
Thermedical 12-Oct-17 Waltham, MA Later Stage VC
Developer of a thermal ablation therapy designed to treat cancer and
cardiac arrhythmias. 8.75
Undisclosed
Investors
VirionHealth 12-Oct-17
Coventry, United
Kingdom Early Stage VC
Developer of biological antivirals created to offer improved therapeutics
for respiratory viral infections. 17.28 Abingworth
ENTvantage Dx 13-Oct-17 Austin, TX Early Stage VC
Developer of an in-office diagnostic test kit designed to determine the
cause of ear, nose, and throat illnesses. 3.30
Keiretsu Forum,
Undisclosed
Investors
FirstString Research 13-Oct-17 Mount Pleasan, SC Later Stage VC
Provider of therapeutics designed to engage in the translation of cell-cell
communication and cell-cell adhesion science into a pipeline of drugs for
wound healing and complex tissue regeneration. 6.58
Undisclosed
Investors
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 8
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Prima-Temp 13-Oct-17 Boulder, CO Later Stage VC
Developer of a device designed to provide precise and accurate core body
temperature measurements. 5.43
Undisclosed
Investors
Quadron Capital (QCC) 13-Oct-17 Vancouver, Canada PIPE
Provider of ancillary equipment, products, and services designed and
structured to address the complex needs and requirements of authorized
cannabis industry participants. 0.81
Undisclosed
Investors
SlipChip 13-Oct-17 Chicago, IL Early Stage VC
Developer of a disruptive microfluidic platform designed to offer
quantitative and digital nucleic acid analysis. 28.94
Undisclosed
Investors
LambdaVision 16-Oct-17 Farmington, CT Early Stage VC
Developer of a protein-based, retinal implant technology that utilizes a
light-activated protein to stimulate the retinas of patients with impaired
vision or sight loss due to retinal degenerative diseases. 0.50
Connecticut
Innovations
Aperiomics 17-Oct-17 Ashburn, VA Seed Round
Developer and provider of a disease diagnosis technology that can
simultaneously test for all pathogens. 0.51
Pipeline Angels,
Chemical Angel
Network
Cydan 17-Oct-17 Cambridge, MA Early Stage VC
Operator of an orphan drug accelerator designed to accelerate therapies
through clinical, regulatory, and commercial development for treating
patients with more than 7,000 rare diseases with approximately 400
approved treatments. 34.00
New Enterprise
Associates,
Longitude Capital,
Pfizer Venture
Investments,
Alexandria Venture
Investments,
Lundbeckfond
Ventures
DiFusion Technologies 17-Oct-17 Austin, TX Angel
Developer of metallic ion therapeutic agents technology designed for
antimicrobial, cellular repair, tissue regeneration, bone growth, scaffold
construction, and increased angiogenesis. 3.47
Undisclosed
Investors
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 9
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Forty Seven 17-Oct-17 Menlo Park, CA Early Stage VC Developer of next generation immuno-oncology therapies. 75.00
Wellington
Management, Clarus
Ventures,
Lightspeed Venture
Partners, Sutter Hill
Ventures, GV
Gemini Therapeutics 17-Oct-17 Cambridge, MA Early Stage VC
Developer of precision therapeutics created to treat genetically-defined dry
age-related macular degeneration and associated rare genetic diseases. 42.50
Atlas Venture,
Lightstone
Ventures, OrbiMed
Lumicell 17-Oct-17 Wellesley, MA Later Stage VC
Developer of an intraoperative imaging system that includes a margin-
targeted injectable imaging agent and hand-held imaging device that gives
surgeons real-time visual feedback of residual cancer in the tumor bed. 27.48
Kodiak Venture
Partners, Launch
Capital, BlueIO,
Sigmas Emerging
Markets,
Undisclosed
Investors
Mission Bio 17-Oct-17 San Francisco, CA Early Stage VC
Developer of technologies to analyze single cells within complex biological
systems designed to detect critical information not observable from bulk
sample analysis. 10.00
Mayfield Fund,
Keiretsu Forum,
Keiretsu Capital
TAI Diagnostics 17-Oct-17 Milwaukee, WI Early Stage VC
Developer of a non-invasive and highly sensitive diagnostic test designed
to monitor the health of transplanted organs. 1.77
Undisclosed
Investors
Critical Outcome
Technologies (COT) 18-Oct-17 London, Canada PIPE
Developer of targeted therapeutic products for ovarian and other
gynecological cancers that help restore normal cell signaling in cancer with
p53 mutations. 2.07
Undisclosed
Investors
CureVac 18-Oct-17 Tübingen, Germany Later Stage VC
Developer of mRNA-molecules for therapeutic and prophylactic vaccines
designed to instruct the human body to produce its own proteins to fight a
wide range of diseases. 53.64
Eli Lilly and
Company
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 10
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Kairos BioMedical 18-Oct-17 Honolulu, HI Angel
Owner and operator of an evidence-based biomedical company that
discovers, develops, and commercializes immuno preventative and
therapeutic products in partnership with leading companies and
institutions. 0.18
Undisclosed
Investors
Miromatrix 18-Oct-17 Eden Prairie, MN Later Stage VC
Developer of a perfusion decellularization technology designed to
manufacture human organs for transplantation. 1.71
Undisclosed
Investors
Prenetics 18-Oct-17
Quarry Bay, Hong
Kong Later Stage VC
Developer of a pharmacogenomics platform designed to offer
personalized, predictive, and preventive treatments. 40.00
Beyond Ventures
and Alibaba
Entrepreneurs
Fund; Yuantai
Investment Partners,
MFUND, eGarden
Ventures
Seventh Sense
Biosystems 18-Oct-17 Medford, MA Later Stage VC
Developer of a blood collection device designed to make blood testing
more convenient and virtually painless. 12.50
Novartis, LabCorp
and Polaris Partners,
Ionis
Pharmaceuticals,
Flagship Ventures
Ambry Genetics 19-Oct-17 Aliso Viejo, CA
PE Growth/
Expansion
Operator of a genetics diagnostics company designed to provide a
comprehensive suite of genetic testing applications for inherited and non-
inherited diseases. 400.00
Innovation Network
Corporation of
Japan
Claret Medical 19-Oct-17 Santa Rosa, CA Later Stage VC
Developer of a cerebral protection system designed to reduce the risk of
stroke during transcatheter aortic valve replacement. 21.21
Lightstone
Ventures, Easton
Capital Investment
Group, HealthCor
Partners
Management,
Incept, Santé
Ventures
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 11
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
Helix BioPharma (HBP) 19-Oct-17
Richmond Hill,
Canada PIPE
Developer of an oncology platform technology designed to induce an
increase in pH locally at the site of cancerous cells in the body to create an
environment inhospitable to their continued growth and survival. 4.91
Undisclosed
Investors
Microbix Biosystems
(MBX) 19-Oct-17 Mississauga, Canada PIPE
Manufacturer and distributor of infectious disease antigens and biological
products for the global diagnostics industry, notably antigens used in
immunoassays or quality assurance and proficiency testing controls. 1.89
Undisclosed
Investors
Replicel Life Sciences
(RP) 19-Oct-17 Vancouver, Canada PIPE Developer of drugs intended for autologous cell therapies. 1.15
Undisclosed
Investors
Synthego 19-Oct-17 Redwood City, CA Early Stage VC Developer of a precision tool to automate genome engineering research. Undisclosed Intel Capital
Veritas Pharma (VRT) 19-Oct-17 Vancouver, Canada PIPE
Developer of innovative medicinal cannabis cultivars for specific disease
conditions such as chronic pain, emesis, and epilepsy. 2.61
Marapharm
Ventures,
Undisclosed
Investors
Hubei 377
Biotechnology
Company 20-Oct-17 Beijing, China
Secondary
Transaction -
Private
Manufacturer of biotechnological devices, including DNA and RNA
synthesis instruments, gene analyzers, synthesizers, amplifiers, protein
purifiers, automated workstations, and other related products. 15.90
Anhui Anke
Biotechnology
Prelude Therapeutics 20-Oct-17 Newark, DE Angel
Developer of medicines targeting chromatin function for the treatment of
cancers and rare diseases. 12.00
Undisclosed
Investors
RenovaCare (RCAR) 20-Oct-17 New York, NY PIPE
Developer of autologous stem cell therapies, including treatments that
target the skin, intended for regeneration of human organs. 2.30
Undisclosed
Investors
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 12
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
ADC Therapeutics 23-Oct-17
Epalinges,
Switzerland Early Stage VC
Developer of antibody and non-antibody drug conjugate products that
target hematological cancers and tumor cells. 200.00
Auven Therapeutics,
Wild Family Office,
AstraZeneca,
Redmile Group,
Undisclosed
Investors
Appili Therapeutics 23-Oct-17 Halifax, Canada Early Stage VC Developer of oral antibiotics for the treatment of infectious diseases. 3.06
Innovacorp,
Undisclosed
Investors
GeneCapture 23-Oct-17 Huntsville, AL Angel
Developer of medical diagnostic devices designed to detect and identify
pathogens. 0.17
Undisclosed
Investors
MYM Nutraceuticals
(MYM) 23-Oct-17 Vancouver, Canada PIPE
Provider of bio-pharmaceutical research services intended to produce
quality cannabis growing facilities and developer of high-end organic
medicinal marijuana supplements and topical products. 3.46
Undisclosed
Investors
Purigen Biosystems 23-Oct-17 Pleasanton, CA Early Stage VC
Developer of an anisotachophoresis chip for nucleic acid preparation to be
used for genomic analyses. 20.85
Roche Venture
Fund, Startx, 5AM
Ventures, Western
Investments Capital,
Undisclosed
Investors
Helixbind 24-Oct-17 Marlborough, MA Angel
Developer of a pathogen identification platform that offers rapid detection
and unequivocal identification of bloodstream infections direct from a
whole blood specimen and without the need for blood culture. 286.00
Undisclosed
Investors
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 13
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
ImmuneTarget 24-Oct-17 San Diego, CA Angel
Developer of a research platform for targeted therapies created to treat
cancers and autoimmune diseases. 0.86
Undisclosed
Investors
Proteon
Pharmaceuticals 24-Oct-17 Lodz, Poland Early Stage VC
Developer of bacteriophage-based products used as an alternative to
antibiotics in combating pathogenic bacteria, including antibiotic resistant
microbes. Undisclosed Aqua-Spark
Sirona Biochem (SBM) 24-Oct-17 Vancouver, Canada PIPE
Developer of a proprietary platform technology with a specialization in the
stabilization of carbohydrate molecules for the cosmetic and drug
discovery industries. 0.64
Undisclosed
Investors
YmAbs 24-Oct-17 New York, NY Early Stage VC
Developer of immunotherapycancer treatments created to drive multiple
product candidates in select solid tumor cancers. 50.00
HBM Healthcare
Investments,
Undisclosed
Investors
Gemneo Bioscience 25-Oct-17 Scottsdale, AZ Angel
Developer of an immune cell profiling technology designed to provide
more optimal cancer treatments and help physicians better understand and
tailor treatments around individual patient's disease and immune responses. 0.10
Undisclosed
Investors
Waverley Pharma
(WAVE) 25-Oct-17 Winnipeg, Canada PIPE Developer of small molecule therapeutics for the treatment of cancer. 4.47
Undisclosed
Investors
Celsee Diagnostics 26-Oct-17 Plymouth, MI Later Stage VC
Developer of a fully-automated circulating tumor cell detection system that
has the ability to analyze biomarkers at a single-cell level at the site of
collection. 7.91
Undisclosed
Investors
Whistler Medical
Marijuana 26-Oct-17 Whistler, Canada Angel Producer of organic medical marijuana. 0.40
Undisclosed
Investors
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 14
Monthly Healthcare Review
October 2017
Company Name
Last
Financing
Date
HQ Location Round Description
Last
Financing
Size
(Millions)
Investor(s)
Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced
over the previous month.
BioTuring 27-Oct-17 San Diego, CA Angel
Developer of a cloud-based software platform utilizing machine learning
and bioinformatics algorithms to store and analyze genomic data. 1.02
Undisclosed
Investors
Kymera 30-Oct-17 Cambridge, MA Early Stage VC
Operator of a biotech firm enaging in the field of targeted protein
degradation to access the body's innate protein recycling machinery. 30.00
Atlas Venture, Lilly
Ventures, Amgen
Ventures
Maxwell MRI 30-Oct-17 Brisbane, Australia Early Stage VC
Provider of a prostate cancer detection and diagnosis platform that
combines deep learning with modern medical imaging and integrates with
existing PACS systems. Undisclosed
Main Sequence
Ventures
Personal Genome
Diagnostics 30-Oct-17 Baltimore, MD Later Stage VC
Developer of cancer genome testing products designed to help in
identifying tumor mutations with accuracy by identifying alterations in
complex cancer genomes. 65.37
Undisclosed
Investors
Ribometrix 31-Oct-17 Greenville, NC Seed Round
Developer of RNA-targeted small molecule drugs created for the
treatment of rare, orphan, and unmet human diseases. 7.50
SV Health Investors,
Hatteras Venture
Partners, AbbVie
Ventures, MP
Healthcare Venture
Management,
Alexandria Venture
Investments
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 15
Monthly Healthcare Review
October 2017
Acquirer Target HQ Location Date DescriptionTransaction
Value (Millions)
Stallergenes Greer Medic Savoure Dutton, Canada 2-Oct-17
Provider of allergy immunotherapy products, including diagnostics and AIT
treatment products. Undisclosed
Abbott Laboratories Alere Waltham, MA 3-Oct-17
Manufacturer of consumer and professional medical diagnostic products designed
for the detection of diseases. 4600.00
Undisclosed Apicore US Somerset, NJ 3-Oct-17
Developer and manufacturer of specialty active pharmaceutical ingredients and
pharmaceuticals. 105.00
Gilead Sciences Kite Pharma Santa Monica, CA 3-Oct-17
Developer of active cancer immunotherapies that express either a chimeric
antigen receptor or a T-cell receptor, addressing both hematological and solid
tumor cancers. 12000.00
Fagron All Chemistry Sao Paulo, Brazil 5-Oct-17
Distributor of pharmaceutical raw materials and provider of testing and
microbiological analysis. Undisclosed
Medtronic
Animas (Insulin
pump business) Wayne, PA 5-Oct-17
Manufacturer and developer of medicines and vaccines for the treatment of
diabetes. Undisclosed
Prescient Medicine PGxl Laboratories Louisville, KY 5-Oct-17
Provider of pharmacogenetics services engaged with the development of
personalized medicine at the level of discovery, assay development, and clinical
testing. Undisclosed
Emergent BioSolutions ACAM2000 Paris, France 6-Oct-17
Developer of a vaccine for active immunization against smallpox disease for
persons determined to be at high risk for smallpox infection. 125.00
First Coin Capital
Bradmer
Pharmaceuticals
(BMR.H) Toronto, Canada 10-Oct-17 Provider of new and innovative cancer therapies. Undisclosed
Kerry Group Ganeden Biotech
Mayfield Heights,
OH 11-Oct-17
Developer of patented probiotic ingredients designed for making over-the-counter
probiotic products. Undisclosed
Lupin
Symbiomix
Therapeutics Newark, NJ 11-Oct-17
Developer of a potent, next-generation, 5-nitroimidazole antibiotic with enhanced
pharmacokinetic properties that makes efficacious and well-tolerated delivery in a
single dose, enabling patients to get treated from bacterial vaginosis. 150.00
Erkafarm
Rosta Group
(Certain
Subsidiaries)
Saint Petersburg,
Russia 12-Oct-17 Wholesaler and retailer of pharmaceutical products. Undisclosed
Priority Aviation Telluride Health Telluride, CO 12-Oct-17 Operator of a medical cannabis enterprise. Undisclosed
Mergers and AcquisitionsThe following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous
month.
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 16
Monthly Healthcare Review
October 2017
Acquirer Target HQ Location Date DescriptionTransaction
Value (Millions)
Mergers and AcquisitionsThe following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous
month.
Karo Pharma Weifa Oslo, Norway 12-Oct-17
Provider of pharmaceutical drugs for menstrual pain, headaches, swelling and pain
in muscles and joints, wound treatment, and other areas. 163.61
Bracco Imaging SurgVision Harde, Netherlands 18-Oct-17
Provider of a molecular surgical imaging technology designed to discriminate
between healthy and cancerous tissue. Undisclosed
Fortive Landauer (LDR) Glenwood, IL 19-Oct-17
Provider of integrated radiation safety products and services intended to improve
public health and safety by advancing research, technology, and services related to
radiation measurement and medical physics. 770.00
Catalent
Catalent
Bloomington Bloomington, IN 23-Oct-17
Provider of advanced delivery technologies and development solutions for drugs,
biologics, and consumer health products 950.00
Finch Therapeutics Crestovo Cambridge, MA 23-Oct-17
Developer of an orally-administered microbiome designed to deliver novel
therapeutics that involves transfer of good bacteria from one person's gut to
another. Undisclosed
Clinigen Group
International
Medical
Management
Company Minato, Japan 23-Oct-17
Supplier of unlicensed medicines, pharmaceuticals, medical equipment, and
cosmetics. Undisclosed
Grey Cloak Tech Eqova Life Sciences Denver, CO 24-Oct-17
Developer of clinical grade full spectrum hemp oil products developed in
compliance with cGMP, formulated by medical experts with natural ingredients
combined together, and are sold under the CannaBio brand via partnerships with
licensed medical practitioners to use with their patients. Undisclosed
Merck & Co Rigontec Munich, Germany 26-Oct-17 Developer of RNA-based immuno-therapeutics for cancer and viral diseases. 553.06
Maricann Group
NanoLeaf
Technologies Toronto, Canada 27-Oct-17
Operator of a biotechnology company that processes licensing rights to a number
of globally patented technologies that provide proven pharmaceutical,
nutraceutical, cosmetic, and functional beverage drug delivery formulations. 31.31
Source: Pitchbook
Compiled by: Lea Keller and Morgan Reape 17
Top Related